- Recce Pharmaceuticals (RCE) secures a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529
- This is the company's fourth of five patents to be granted, following China, Japan and Europe, with only Australia remaining
- The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion)
Read the Full Article on The Market Herald here
Recce Pharmaceuticals (ASX:RCE) granted US patent
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
-0.020(3.23%) |
Mkt cap ! $122.3M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 60.0¢ | 58.0¢ | $30.77K | 51.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 17599 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
59.5¢ |
Change
-0.020 ( 2.46 %) |
||||
| Open | High | Low | Volume | ||
| 58.5¢ | 59.5¢ | 58.0¢ | 25074 | ||
| Last updated 15.53pm 21/05/2024 ? | |||||
| RCE (ASX) Chart |